drugset
drugset / Trial / NCT04994912

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

NCT04994912 ↗

Phase 1 Completed 35 enrolled Elixiron Immunotherapeutics (Hong Kong) Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.

Timeline

Start
2021-10-01
Primary completion
2025-01-07
Completion
2025-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject EI-001 Monoclonal antibody — Intravenous

Indications

No indication recorded.